These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15288254)

  • 1. Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases.
    Mazitschek R; Giannis A
    Curr Opin Chem Biol; 2004 Aug; 8(4):432-41. PubMed ID: 15288254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents.
    Morin MJ
    Oncogene; 2000 Dec; 19(56):6574-83. PubMed ID: 11426642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.
    Mendel DB; Laird AD; Smolich BD; Blake RA; Liang C; Hannah AL; Shaheen RM; Ellis LM; Weitman S; Shawver LK; Cherrington JM
    Anticancer Drug Des; 2000 Feb; 15(1):29-41. PubMed ID: 10888034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor tyrosine kinase inhibitors as anti-angiogenic agents.
    Kim DW; Lu B; Hallahan DE
    Curr Opin Investig Drugs; 2004 Jun; 5(6):597-604. PubMed ID: 15242247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.
    Broxterman HJ; Georgopapadakou NH
    Drug Resist Updat; 2005 Aug; 8(4):183-97. PubMed ID: 16154800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold.
    Kissau L; Stahl P; Mazitschek R; Giannis A; Waldmann H
    J Med Chem; 2003 Jul; 46(14):2917-31. PubMed ID: 12825933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of growth factor antagonists with antiangiogenic and antitumor properties.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6566-73. PubMed ID: 11426641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth factor receptor kinase inhibitors: recent progress and clinical impact.
    Dumas J
    Curr Opin Drug Discov Devel; 2001 Jul; 4(4):378-89. PubMed ID: 11727303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of tyrosine kinase inhibitors in cancer therapy.
    Arora A; Scholar EM
    J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted agents for the treatment of advanced renal cell carcinoma.
    Stadler WM
    Cancer; 2005 Dec; 104(11):2323-33. PubMed ID: 16240452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
    Newton HB
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
    Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
    Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tyrosine kinase receptor-ras-ERK signal transduction pathway as therapeutic tarfet in cancer].
    Leirdal M; Sioud M
    Tidsskr Nor Laegeforen; 2002 Jan; 122(2):178-82. PubMed ID: 11873574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Technology evaluation: IMC-1C11, ImClone Systems.
    Hunt S
    Curr Opin Mol Ther; 2001 Aug; 3(4):418-24. PubMed ID: 11525567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New therapeutic approaches in glioblastomas].
    Le Guilloux J; Carpentier AF
    Rev Neurol (Paris); 2008; 164(6-7):554-9. PubMed ID: 18565354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
    Idbaih A; Ducray F; Sierra Del Rio M; Hoang-Xuan K; Delattre JY
    Oncologist; 2008 Sep; 13(9):978-92. PubMed ID: 18779539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining molecular therapeutics with radiotherapy for head and neck cancer.
    Riesterer O; Milas L; Ang KK
    J Surg Oncol; 2008 Jun; 97(8):708-11. PubMed ID: 18493923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenesis inhibitors in the treatment of lung cancer.
    Sun S; Schiller JH
    Crit Rev Oncol Hematol; 2007 May; 62(2):93-104. PubMed ID: 17306557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting growth factors and angiogenesis; using small molecules in malignancy.
    Wanebo HJ; Argiris A; Bergsland E; Agarwala S; Rugo H
    Cancer Metastasis Rev; 2006 Jun; 25(2):279-92. PubMed ID: 16770540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.